Business Context and Reporting Period
This Form 8-K is filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on November 14, 2023. The report addresses critical compliance issues regarding the company's continued listing on The Nasdaq Capital Market under trading symbols ATNF and ATNFW.
Key Financial Metrics and Liquidity
The filing references the company's Quarterly Report on Form 10-Q for the period ended September 30, 2023, to highlight a specific liquidity and equity metric:
- Stockholders' Equity: The company reported a stockholders' deficit of ($149,327).
- Nasdaq Requirement: Listing Rule 5550(b)(1) requires a minimum stockholders' equity of $2,500,000.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, or debt.
Material Changes and Compliance Status
The company faces two distinct material compliance failures with Nasdaq:
- Shareholder Approval Violation (Rule 5635(d)):
- The company issued securities (common stock, pre-funded warrants, and common warrants) in an August 2023 offering without prior shareholder approval, as the issuance exceeded 20% of pre-transaction shares at a price below the minimum threshold.
- Status: Nasdaq granted an extension until December 15, 2023, for the company to complete transactions in its compliance plan to remedy this violation.
- Minimum Stockholders' Equity Violation (Rule 5550(b)(1)):
- On November 15, 2023, the company received notice that its stockholders' deficit of ($149,327) failed to meet the $2.5 million minimum requirement.
- Status: The company has until January 2, 2024, to submit a plan to regain compliance. If accepted, it may receive up to 180 days to evidence compliance.
Outlook, Risks, and Management Commentary
Management is actively evaluating courses of action to regain compliance with both listing standards. However, the filing explicitly states there can be no assurance that the company's plans will be accepted or that compliance will be achieved.
- Delisting Risk: If the company fails to satisfy the terms of its compliance plans by the respective deadlines (December 15, 2023, for Rule 5635(d) and the 180-day period following plan acceptance for Rule 5550(b)(1)), Nasdaq may notify the company that its securities will be delisted.
- Appeal Rights: In the event of a delisting determination, the company retains the right to appeal to a Nasdaq Hearings Panel.
- Current Trading Status: As of the filing date, the noncompliance notices have had no immediate impact on the continued listing or trading of the company's common stock.
Investor Verification Checklist
- Verify the company's progress on the compliance plan for Rule 5635(d) by the December 15, 2023 deadline.
- Monitor the submission and acceptance of the plan to address the stockholders' equity deficit by January 2, 2024.
- Confirm whether the company has successfully amended the terms of its prior offering to satisfy shareholder approval requirements.
- Check for any subsequent announcements regarding the company's stockholders' equity position or potential capital raises to eliminate the deficit.
- Review the company's minimum bid price status, as the filing notes the company is also not currently in compliance with the $1.00 minimum bid price requirement.